The Wolverine Stack: what BPC-157 and TB-500 together could do

Picture the protocol that does the lot. One shot rebuilds the blood supply into a beaten-up tendon; the other tells the repair cells to show up and get to work. Run the two together and the body does what it did at twenty-two — repairs fast, knits clean, comes back from the thing you’d half given up on. That’s the promise stamped on the Wolverine Stack. And it’s a genuinely good idea.

BPC-157 and TB-500. Two peptides, one envelope, one fantasy — a repair-everything protocol named, like this brand, after the healing factor rather than the fighting one. The appeal isn’t hype. It’s that the two are supposed to do different repair jobs. Different is exactly what you want when you pair two things.

So let’s take the pairing seriously, in the order it deserves: what it’s supposed to do for you, why the biology behind it is worth the excitement, and then the one boundary that matters more here than almost anywhere else on this site.

What the stack is supposed to do for you

Start with the upside, because it’s real and it’s the whole reason anyone reaches for both.

BPC-157’s headline job is plumbing. A torn tendon knits slowly partly because it barely has a blood supply to begin with — no supply lines, no way for oxygen and repair signals to reach the damage. BPC-157’s proposed trick, mapped across animal work in the 2025 Pharmaceuticals review by Józwiak et al. (PMID 40005999), is to grow new blood vessels straight into the wound. Feed the site, and the site can rebuild.

TB-500 works a different angle. Its named target, thymosin β4, is a peptide your own cells already make to run their internal scaffolding — the framework a cell uses to change shape and crawl. Philp and Kleinman’s 2010 review walks through animal wounds — skin, cornea, heart — where that signal pulls repair cells toward the damage and helps them organise once they arrive. Put plainly: BPC-157 lays the supply lines, and TB-500’s protein gets the workers to the site and moving.

Two jobs, no overlap. One feeds the repair, the other mobilises it. On a whiteboard that’s a beautiful pairing — not two peptides throwing the same punch twice, but two halves of one job.

Why the two-halves idea is worth the excitement

The best thing about the pairing is also the simplest: the two mechanisms don’t step on each other.

A bad stack is two compounds doing the same thing — you double the cost and the side-effect risk to buy one effect. This isn’t that. Growing blood vessels and moving repair cells are genuinely separate levers on the same outcome, which is exactly the shape a good stack should have. A 2025 systematic review in orthopaedic sports medicine (PMID 40756949) already casts BPC-157 as an emerging candidate across tendon, ligament, and bone, and a 2026 Pharmaceuticals review by Matek et al. (PMID 41754849) reads it alongside the growth factors that drive repair at the junctions where tendon meets bone — the slowest places in the body to come back. There’s real interest in that first lever.

The second lever has a bonus attached. Wang and colleagues (2022) trace how thymosin β4 breaks down into a smaller fragment, Ac-SDKP, that pushes back against scar tissue in liver, kidney, heart, and lung models. Scar is the enemy of a clean tendon repair — the reason a healed tendon often isn’t as good as the original. So the theory has a real shape to it: feed the site, move the cells, hold back the scar. If someone sat down to design a repair stack from a blank page, it might well look a lot like this one.

The honest boundary — and here it matters more than usual

Now the part the envelope doesn’t print. Everything above is theory.

Not one of those complementary jobs has been measured with the two compounds actually dosed together. There is no combination trial. No animal study of BPC-157 and TB-500 co-dosed in an injury. No pharmacokinetic work on whether they interact, compete to get absorbed, or change how fast the body clears each other. The stack is two single-compound stories stapled at a seam, and the seam is the one thing nobody has tested.

And the single-compound stories are themselves thin. BPC-157’s human record is a Phase 1 pharmacokinetic trial that registered in 2015 and never reported a result (NCT02637284, ClinicalTrials.gov status Unknown), a two-person intravenous safety pilot with no efficacy endpoint (Lee and Burgess 2025), and — new this year — the first controlled trial in an actual injury, a Phase 2 hamstring-strain study (NCT07437547) that’s recruiting with no read-out. TB-500’s human tendon file is blank: no Phase 1, no registered trial, no case series. The one tendon-adjacent paper anyone points to is Wu and colleagues (2020) — thymosin β4 loaded onto a synthetic scaffold, human cells migrating in a dish. Well-designed work. Cells on plastic, not a tendon, not an animal, not a person. The 2026 Sports Medicine review by Mendias and Awan names both peptides in its list of compounds sold well ahead of their evidence.

There’s a second catch, and it’s specific to TB-500. The vial sold under that name isn’t always the protein the research is on. Sometimes it’s full thymosin β4; sometimes a short seven-piece fragment; sometimes a smaller piece again. The evidence and the syringe don’t reliably hold the same molecule.

So the stack asks you to trust three things at once. That each peptide does its job. That the two work together. That the second one is even what the label says. None of the three has been checked.

If your question is narrower — not both, but which one for a specific injury — that’s a different comparison, and we laid it out in BPC-157 vs TB-500 for injury recovery. This page is about the pairing itself.

Where the regulators put the pair

The two peptides do meet in exactly one official place, and it isn’t a lab bench.

It’s the July 23, 2026 FDA Pharmacy Compounding Advisory Committee docket, per the April 2026 Federal Register notice. Both are on the July 23 session, evaluated against the Section 503A bulk drug substances list. Read the indications, though, and the pairing steps apart again. BPC-157 is under review for ulcerative colitis — a gut condition, drawing on its original gastric research. TB-500 is under review for wound healing. Neither is being evaluated for injury recovery, and certainly not for the two-together protocol.

That distinction does real work. PCAC is advisory: it recommends, and the FDA decides later through rulemaking. A Section 503A listing — the lane the committee is being asked to open — would let a US-licensed compounding pharmacy make either drug for a named patient with a prescription, for the listed use. What that whole process actually decides is its own story, told in what a PCAC review actually is. Both peptides are WADA-prohibited at all times, TB-500 under the S2 category — if you’re tested, they’re banned in and out of competition. The committee hasn’t voted. Yes, no, and yes-with-conditions are all still live, and what happens in late July moves the conversation for each peptide at once.

The version of this stack worth waiting for

Here’s the thing worth holding onto: the idea is good. The pairing might genuinely turn out to be more than the sum of two thin files — two levers that work better pulled together than apart.

But the only way anyone finds out is to run it properly. A doctor who saw your scan deciding whether two peptides belong in one plan for your specific injury. A US-licensed pharmacy compounding what the label actually promises. An assay on every batch before it ships. That’s what Wolverine Health is being built to be — not two vials that happened to share an envelope, but a protocol somebody signs their name to. It isn’t open yet, and we’re not going to pretend it is. The July 23 PCAC meeting decides what’s even available, and we’d rather tell you what the committee clears — for BPC-157, for TB-500 — than what we’re hoping for.

Leave your email. We’ll write to you the day this stops being two vials in an envelope and starts being a protocol with a name on it.